Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Approccio Cardiologico Al Paziente Sottoposto A Trattamento Antitumorale. Documento Primo

L. Boccardi, D. Cardinale, M. Civelli, C. Lestuzzi, C. Materazzo, N. Maurea, I. Monte, Stefano Oliva, P. Piotti, G. Quattrocchi, E. Rossi, G. Toglia
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Riassunto Con il miglioramento della sopravvivenza dei pazienti oncologici, negli ultimi anni, si e incrementato significativamente il rilievo di complicanze cardiovascolari direttamente o indirettamente collegabili ai trattamenti antitumorali effettuati, anche a notevole distanza di tempo. Per rispondere a questa esigenza di salvaguardia cardiovascolare del paziente oncologico, la Societa Italiana di Ecografia Cardiovascolare (SIEC) ha recentemente istituito un Gruppo di Studio di Ecocardio-Oncologia. Tra gli obiettivi che il Gruppo di Studio ha ritenuto necessario individuare, vi sono sia obiettivi di tipo assistenziale e divulgativo, come la promozione di convegni, corsi e meeting sull’argomento, sia obiettivi di tipo scientifico. Sono state definite, infatti, sette aree di interesse clinico-scientifico per sostenere e promuovere la ricerca nel campo della prevenzione, della diagnosi precoce e del trattamento efficace della cardiotossicita da antiblastici. Il Documento primo rappresenta il documento programmatico del Gruppo di Studio.
This paper references
10.1200/JCO.2006.09.1611
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
T. Suter (2007)
10.7326/0003-4819-125-1-199607010-00008
Anthracycline-Induced Cardiotoxicity
K. Shan (1996)
10.1007/s00432-007-0250-9
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study
C. Kosmas (2007)
10.1161/01.CIR.0000133187.74800.B9
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
E. T. Yeh (2004)
10.1200/JCO.2004.06.022
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
J. Silber (2004)
10.1007/s10549-007-9803-5
The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines
G. Dranitsaris (2007)
10.1016/0002-9343(87)90212-9
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
10.1016/0735-1097(91)90836-X
Quantitative assessment of ultrasonic myocardial reflectivity in hypertrophic cardiomyopathy.
F. Lattanzi (1991)
10.1016/J.JACC.2007.06.037
Early breast cancer therapy and cardiovascular injury.
L. Jones (2007)
10.4143/crt.2008.40.3.121
Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity.
Ho Sup Lee (2008)
10.1517/14656566.8.8.1039
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
E. Barry (2007)
10.1053/J.SEMINONCOL.2004.08.006
Cardiac safety of liposomal anthracyclines.
M. Ewer (2004)
10.1200/JCO.2007.10.9777
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J. Carver (2007)
10.1200/JCO.2008.21.2134
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
E. Winer (2009)
10.1161/01.CIR.96.8.2641
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.
S. Lipshultz (1997)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Proceedings of the American Society of Clinical Oncology
J. Korinek (1982)
10.1016/J.AMJCARD.2006.10.063
Acute cardiac functional and morphological changes after Anthracycline infusions in children.
J. Ganame (2007)
10.1016/J.EUJE.2005.04.009
Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study.
S. Tassan-Mangina (2006)
10.1136/hrt.2009.173997
Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study
E. Ho (2010)
10.1038/nrcardio.2009.103
Targeting angiogenesis to restore the microcirculation after reperfused MI
A. M. Laan (2009)
10.1080/02841860903229124
Cardiotoxicity induced by tyrosine kinase inhibitors
George S Orphanos (2009)
10.1161/01.CIR.0000130926.51766.CC
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
D. Cardinale (2004)
10.1056/NEJM199506293322602
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
S. Lipshultz (1995)
10.1056/NEJM199809243391307
Doxorubicin-induced cardiomyopathy.
P. Singal (1998)
10.1016/j.echo.2008.10.008
Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough.
B. Eidem (2008)
10.1016/S0002-8703(97)70205-9
Cardiovascular responses to dynamic submaximal exercise in children previously treated with anthracycline.
D. Johnson (1997)
10.1016/J.IJCARD.2005.07.029
Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity.
M. Civelli (2006)
10.1093/ANNONC/MDF132
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
B. V. Jensen (2002)
10.1159/000262452
Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin – An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity
Ilona Steppan (2009)
10.1021/tx800002r
Cardiotoxicity of antitumor drugs.
P. Menna (2008)
10.2165/00002018-200022040-00002
Cardiotoxicity of Chemotherapeutic Agents
V. Pai (2000)
10.1053/J.SEMINONCOL.2006.04.019
Exposure to anthracyclines during childhood causes cardiac injury.
S. Lipshultz (2006)
10.1016/S0735-1097(87)80099-2
Alterations in left ventricular diastolic function with doxorubicin therapy.
B. H. Lee (1987)
10.1093/EURHEARTJ/EHL013
Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury.
T. Neilan (2006)
10.1200/JCO.2005.04.8678
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
R. Herbst (2006)
10.1053/J.SEMINONCOL.2006.04.021
Anthracycline-induced cardiotoxicity in adult hematologic malignancies.
S. Johnson (2006)
10.1016/0735-1097(92)90138-D
Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans.
M. Stoddard (1992)
10.1093/annonc/mdp025
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
G. di Lorenzo (2009)
10.1200/JCO.2006.10.4976
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
M. Pinder (2007)
10.1200/JCO.2010.28.15_SUPPL.E18563
Echocardiography monitoring in patients with Hodgkin's and non-Hodgkin's lymphoma: The Tei-Index evaluation.
Agnese Maria Fioretti (2010)
10.1016/0002-8703(89)90077-X
Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics.
B. Marchandise (1989)
10.1016/j.ijcard.2010.03.003
Cardiac side-effects of cancer chemotherapy.
Jean-Jacques Monsuez (2010)
10.1007/s00432-008-0372-8
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
F. J. F. Broeyer (2008)
10.1067/S0894-7317(03)00425-5
Ultrasonic analysis of anthracycline-induced myocardial damage using cyclic variation of integrated backscatter.
H. Nagai (2003)
10.1093/ANNONC/MDF170
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy.
D. Cardinale (2002)
10.1111/j.1365-2141.2005.05759.x
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
Karlijn A Wouters (2005)
10.1002/14651858.CD003917.pub4
Cardioprotective interventions for cancer patients receiving anthracyclines.
E. C. van Dalen (2011)
10.1161/01.CIR.95.1.140
Recognition of acute cardiac allograft rejection from serial integrated backscatter analyses in human orthotopic heart transplant recipients. Comparison with conventional echocardiography.
C. Angermann (1997)
10.1016/j.echo.2009.01.016
Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy.
D. Jassal (2009)
10.1161/CIRCULATIONAHA.106.635144
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
D. Cardinale (2006)
10.1016/S1470-2045(07)70246-2
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.
A. Verdecchia (2007)
10.1016/S1470-2045(09)70042-7
Cardiovascular toxicity caused by cancer treatment: strategies for early detection.
R. Altena (2009)
10.1002/cncr.11407
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
10.1124/mol.108.050104
Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib
B. Hasinoff (2008)
10.1016/J.HEALUN.2004.12.108
Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.
J. Tallaj (2005)
10.1016/0735-1097(92)90497-B
Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.
S. Klewer (1992)
10.1016/j.jacc.2009.03.095
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
D. Cardinale (2010)
10.1517/14728214.11.4.635
Therapeutic options to target angiogenesis in human malignancies
R. Herbst (2006)



Semantic Scholar Logo Some data provided by SemanticScholar